Table 9.
Logistic regression of uncontrolled systolic blood pressure (SBP) at 90 days (variables with significant odds ratios and 95% confidence interval not crossing 1.00)
| PREVIEW | IMPROVE | ADVANCE | INSIST | eNOVA | BSCORE | EXCELLENT | ||
|---|---|---|---|---|---|---|---|---|
| Patient-related variables | ||||||||
| Age | per year | 1.01 | 1.02 | |||||
| Male gender | if male | 0.57 | ||||||
| SBP at initial diagnosis of hypertension | per mmHg | 1.02 | 1.02 | 1.02 | 1.01 | |||
| SBP at baseline | per mmHg | 1.05 | ||||||
| Controlled SBP at baseline | if present | 0.19 | ||||||
| Diabetes | if present | 8.99 | 5.85 | 7.75 | 8.07 | 5.61 | ||
| Highly vulnerable to uncontrolled hypertension cluster | if present | 1.56 | ||||||
| Total cardiovascular risk: high added risk | if present | 8.55 | ||||||
| Total cardiovascular risk: very high added risk | if present | 2.49 | ||||||
| Conditions and risk factors: no pre-existing | if no pre-existing | 0.63 | ||||||
| Conditions and risk factors: smoker | present | 1.50 | ||||||
| Conditions and risk factors: other | present | (0.52) | ||||||
| Hypercholesterolemia | if present | 1.23 | ||||||
| Concomitant antihypertensive treatment: calcium antagonist | if present | (1.77) | ||||||
| Concomitant antihypertensive treatment: alfa blocker | if present | (2.48) | ||||||
| Concomitant antihypertensive treatment: beta blocker | if present | (1.44) | ||||||
| Nonadherent days in past 4 weeks | per day | 1.01 | ||||||
| Patient-reported nonadherence behavior | if reported | 1.36 | ||||||
| Physician-rated adherence | per point (0–100 scale) | 0.98 | ||||||
| Months since last blood pressure measurement | per month | 1.08 | ||||||
| Physician-related variables | ||||||||
| Years since medical school graduation (in practice) | per year | 1.02 | 1.02 | 1.03 | ||||
| Correct blood pressure values for hypertension diagnosis in diabetic patients | if all correct | (1.66) | ||||||
| Correct blood pressure targets for diabetic patients | if all correct | (2.05) | ||||||
| Correct blood pressure targets for non-diabetic patients | if all correct | 0.61 | ||||||
| Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment initiation | per practice (0–6) | 0.91 | ||||||
| Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment intensification | per practice (0–6) | 0.99 |